BioSyent Inc.
BioSyent Inc. Fundamental Analysis
BioSyent Inc. (BIOYF) shows strong financial fundamentals with a PE ratio of 17.57, profit margin of 19.65%, and ROE of 22.05%. The company generates $0.0B in annual revenue with strong year-over-year growth of 22.90%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 84.7/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze BIOYF's fundamental strength across five key dimensions:
Efficiency Score
ExcellentBIOYF demonstrates superior asset utilization.
Valuation Score
ExcellentBIOYF trades at attractive valuation levels.
Growth Score
ExcellentBIOYF delivers strong and consistent growth momentum.
Financial Health Score
ExcellentBIOYF maintains a strong and stable balance sheet.
Profitability Score
ExcellentBIOYF achieves industry-leading margins.
Key Financial Metrics
Is BIOYF Expensive or Cheap?
P/E Ratio
BIOYF trades at 17.57 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, BIOYF's PEG of 0.67 indicates potential undervaluation.
Price to Book
The market values BioSyent Inc. at 3.52 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 12.35 times EBITDA. This signals the market has high growth expectations.
How Well Does BIOYF Make Money?
Net Profit Margin
For every $100 in sales, BioSyent Inc. keeps $19.65 as profit after all expenses.
Operating Margin
Core operations generate 25.10 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $22.05 in profit for every $100 of shareholder equity.
ROA
BioSyent Inc. generates $14.43 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
BioSyent Inc. generates strong operating cash flow of $13.20M, reflecting robust business health.
Free Cash Flow
BioSyent Inc. generates strong free cash flow of $12.87M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $1.12 in free cash annually.
FCF Yield
BIOYF converts 7.88% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
17.57
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.67
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.52
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.50
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.12
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.89
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.22
vs 25 benchmark
ROA
Return on assets percentage
0.14
vs 25 benchmark
ROCE
Return on capital employed
0.25
vs 25 benchmark
How BIOYF Stacks Against Its Sector Peers
| Metric | BIOYF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 17.57 | 29.35 | Better (Cheaper) |
| ROE | 22.05% | 705.00% | Weak |
| Net Margin | 19.65% | -53441.00% (disorted) | Strong |
| Debt/Equity | 0.12 | 0.39 | Strong (Low Leverage) |
| Current Ratio | 1.89 | 4.01 | Neutral |
| ROA | 14.43% | -19815.00% (disorted) | Strong |
BIOYF outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews BioSyent Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
122.50%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
174.06%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
61.03%
Industry Style: Defensive, Growth, Innovation
High Growth